Chiesi and Protalix Secure EU Nod for Extended Dosing Regimen of Elfabrio

Event summary

  • CHMP issues positive opinion for Elfabrio’s 2mg/kg every-4-weeks dosing regimen in EU, pending EC approval by March 2026.
  • Extended dosing reduces patient burden, cutting infusion center visits from biweekly to monthly.
  • Protalix eligible for $25M milestone payment from Chiesi if EC approves the new regimen.
  • Current U.S. dosing regimen remains 1mg/kg every 2 weeks, highlighting regulatory divergence.
  • Approval based on BRIGHT study and 6-year extension data, demonstrating long-term safety and efficacy.

The big picture

The CHMP’s positive opinion for Elfabrio’s extended dosing regimen reflects a broader industry trend toward patient-centric treatment designs in rare diseases. This approval, if finalized by the EC, could set a precedent for other enzyme replacement therapies, reinforcing Chiesi and Protalix’s leadership in Fabry disease treatment. The $25M milestone underscores the strategic importance of this regulatory win, particularly as competitors like Pfizer navigate similar challenges in the space.

What we're watching

Regulatory Alignment
Whether the U.S. will follow the EU’s lead in approving the extended dosing regimen, given current regulatory divergence.
Commercial Impact
How the reduced dosing burden will affect patient adherence and market penetration in the EU.
Pipeline Validation
The pace at which Protalix’s ProCellEx platform will yield additional regulatory successes.

Related topics

Regulatory Approval